Hancock Jaffe Laboratories Inc ROCE
Was ist das ROCE von Hancock Jaffe Laboratories Inc?
ROCE von Hancock Jaffe Laboratories Inc ist -27.53%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Hancock Jaffe Laboratories Inc
Was macht Hancock Jaffe Laboratories Inc?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Unternehmen mit roce ähnlich Hancock Jaffe Laboratories Inc
- Compass hat ROCE von -27.67%
- Lineage Cell Therapeutics Inc hat ROCE von -27.63%
- Kuya Silver hat ROCE von -27.62%
- Pender Street Capital Corp hat ROCE von -27.61%
- Buckhaven Capital hat ROCE von -27.61%
- Seagen Inc hat ROCE von -27.58%
- Hancock Jaffe Laboratories Inc hat ROCE von -27.53%
- Y-Mabs Therapeutics Inc hat ROCE von -27.49%
- Ramco Systems hat ROCE von -27.47%
- Goldflare Exploration Inc hat ROCE von -27.46%
- Gravitas One Capital hat ROCE von -27.44%
- Arcturus Therapeutics Inc hat ROCE von -27.43%
- Bellus Health Inc hat ROCE von -27.42%